Phase 1 Parkinson's Disease Trial, Recruiting (NCT06356662)

Phase 1 Parkinson's Disease Trial, Recruiting NCT06356662 Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine Condition: Parkinson's Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06356662 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Parkinsons Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with Parkinson's disease at a relatively early to mid stage (rated between 1 and 2.5 on a standard Parkinson's severity scale called the Hoehn and Yahr scale)
People who score 24 or higher on a standard memory and thinking test called the MMSE, indicating no significant cognitive impairment

Who may not be able to join:

People who have another clearly diagnosed neurological condition, such as essential tremor, stroke, or epilepsy
People who have previously had deep brain stimulation or any other type of brain surgery
People with abnormal liver or kidney function test results
People who have a chronic hepatitis B infection or HIV/AIDS
People who have severe depression, schizophrenia, another serious psychiatric condition, or a drug dependency
People who have another serious illness affecting the heart, lungs, liver, or kidneys, a blood disorder, or cancer
Women who are pregnant or breastfeeding, or people aged over 65 years
People who have a known allergy to the study drug or any other medical reason that would make taking the study drug unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06356662

Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Phase: Phase 1

Status: Recruiting

Condition: Parkinson's Disease

More information: https://clinicaltrials.gov/study/NCT06356662

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with Parkinson's disease at a relatively early to mid stage (rated between 1 and 2.5 on a standard Parkinson's severity scale called the Hoehn and Yahr scale)
People who score 24 or higher on a standard memory and thinking test called the MMSE, indicating no significant cognitive impairment

Who may not be able to join:

People who have another clearly diagnosed neurological condition, such as essential tremor, stroke, or epilepsy
People who have previously had deep brain stimulation or any other type of brain surgery
People with abnormal liver or kidney function test results
People who have a chronic hepatitis B infection or HIV/AIDS
People who have severe depression, schizophrenia, another serious psychiatric condition, or a drug dependency
People who have another serious illness affecting the heart, lungs, liver, or kidneys, a blood disorder, or cancer
Women who are pregnant or breastfeeding, or people aged over 65 years
People who have a known allergy to the study drug or any other medical reason that would make taking the study drug unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Registry

ClinicalTrials.gov

Start date

23 January 2024

Est. completion

31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

UPDRS III（Unified Parkinson's Disease Rating Scale part 3）

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov